Interim results of trials of combination of AstraZeneca, Sputnik Light vaccines in Russia expected in early 2021-late 2022
MOSCOW. July 28 (Interfax) - Interim results of the clinical trials of the combination of the Oxford/AstraZeneca Covid-19 vaccine and the Sputnik Light vaccine, developed by Russia's Gamaleya Research Center, are expected to become available in late 2021-early 2022, the AstraZeneca press service in Russia said.
A few days ago, the Russian Health Ministry issued permission to conduct the clinical trials of the vaccines' combination in Russia.
"We hope to receive the interim results of the trials at the end of this year or at the beginning of next year," the press service said in response to a question from Interfax.
"These clinical trials are of great significance not only to the research of the potential of using vaccines' combinations and assessment of their synergy in inducing immune responses, but also to the development of revaccination programs," it said.
A number of countries have approved both the Oxford/AstraZeneca vaccine and the Gamaleya Center's Sputnik V vaccine, it said.
"Vaccine application when the first immunization uses one type of the vaccine and the second immunization uses another vaccine type (heterologous prime-boost vaccination) will help make the vaccination protocol more flexible for the population in these countries," it said.
On July 26, the Russian Health Ministry approved holding the phase 1 and phase 2 clinical trials of the combination of the Oxford/AstraZeneca and the Sputnik Light Covid-19 vaccines in Russia, according to the state register of clinical trial permissions.